Free Trial
NYSE:KD

Kyndryl Q2 2027 Earnings Date & Estimates

Kyndryl logo
$11.94 -0.30 (-2.41%)
As of 10:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Kyndryl is estimated to report Q2 2027 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET

What Analysts Expect from Kyndryl in Q2 2027

Kyndryl is expected to post earnings of $0.3817 per share on revenue of $3.62 billion. In the same quarter a year earlier Kyndryl reported $0.38 per share on revenue of $3.72 billion. Kyndryl last reported on August 5, 2026, posting -$0.12 per share and beating the -$0.1583 consensus estimate. Kyndryl has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.3817
Expected Revenue
$3.62 billion
Prior-Year EPS
$0.38
Prior-Year Revenue
$3.72 billion
Expected EPS Growth
+0.4%
Expected Revenue Growth
-2.6%

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
-$0.12 (Beat by +$0.0383)
Last Quarter Revenue
$3.62 billion
EPS Beat Rate
5 of last 8 quarters

Kyndryl Q2 2027 Earnings FAQ

Kyndryl (NYSE:KD) is estimated to report Q2 2027 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Kyndryl's Q2 2027 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Kyndryl to post earnings of $0.3817 per share for Q2 2027.

The consensus revenue estimate for Kyndryl is $3.62 billion for Q2 2027.

Kyndryl Earnings Headlines

The $42 Billion Breakthrough That Took 40 Years to Arrive
GLP-1, the compound behind Eli Lilly's Mounjaro, was discovered more than 40 years ago. It took four decades for that science to become a drug that generated 65 billion dollars in revenue last year and sent Eli Lilly shares up 323 percent since approval. One little known Midwestern company is working to shorten that timeline. It uses advanced technology to help biotech startups bring new treatments to market faster.tc pixel
Kyndryl : Statement on Solvinity prohibition
See More Kyndryl Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kyndryl? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyndryl and other key companies, straight to your email.

About Kyndryl

Kyndryl (NYSE:KD) (NYSE: KD) is an information technology services company that designs, builds, manages and modernizes mission-critical technology systems for businesses and public-sector organizations. Its services include managed infrastructure, cloud solutions, application management, network and edge services, cybersecurity, data and artificial intelligence, and technology consulting.

The company helps clients operate and transform complex IT environments, including hybrid cloud and traditional on-premises systems. Kyndryl also provides services for mainframe computing, digital workplace technology, enterprise applications and industry-specific technology requirements through alliances with major technology providers.

Kyndryl was formed through the separation of IBM’s managed infrastructure services business and became an independent publicly traded company in November 2021. It serves customers internationally across industries such as financial services, telecommunications, healthcare, manufacturing, government and retail. Martin Schroeter is Kyndryl’s chairman and chief executive officer.

View Kyndryl Profile